Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2014 16:01 ET | Source: TESARO, Inc.

TESARO Announces Closing of $201.25 Million Public Offering of 3.00% Convertible Senior Notes Due 2021, Including Full Exercise of the Underwriters' Option to Purchase Additional Notes

WALTHAM, Mass., Sept. 29, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of $201.25 million aggregate...
September 23, 2014 22:40 ET | Source: TESARO, Inc.

TESARO Announces Pricing of $175 Million of 3.00% Convertible Senior Notes Due 2021

WALTHAM, Mass., Sept. 23, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the pricing of $175 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the...
September 22, 2014 16:01 ET | Source: TESARO, Inc.

TESARO Announces Offering of $165 Million of Convertible Senior Notes Due 2021

WALTHAM, Mass., Sept. 22, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that, subject to market and other conditions, it intends to offer $165 million aggregate principal amount...
September 08, 2014 08:01 ET | Source: TESARO, Inc.

TESARO Announces Submission of Rolapitant New Drug Application (NDA) to U.S. Food and Drug Administration

WALTHAM, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for...
August 21, 2014 08:01 ET | Source: TESARO, Inc.

TESARO Announces Participation at Several Upcoming Investor Conferences

WALTHAM, Mass., Aug. 21, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and...
July 24, 2014 16:01 ET | Source: TESARO, Inc.

TESARO Announces Second-Quarter 2014 Operating Results

Oral Rolapitant New Drug Application (NDA) on Track for Submission to U.S. FDA Enrollment in Niraparib NOVA Trial Non-gBRCA Cohort Expected to Be Complete at Year End Enrollment in Phase...
July 24, 2014 16:00 ET | Source: TESARO, Inc.

TESARO Appoints Mary Lynne Hedley, Ph.D., as Chief Operating Officer

WALTHAM, Mass., July 24, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of...
July 10, 2014 16:01 ET | Source: TESARO, Inc.

TESARO to Announce Second-Quarter 2014 Financial Results on July 24, 2014

WALTHAM, Mass., July 10, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second-quarter 2014 financial results on Thursday, July 24, 2014, after the close of the U.S. financial...
June 27, 2014 11:00 ET | Source: TESARO, Inc.

TESARO Summarizes Rolapitant Data Presented at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer

MIAMI, June 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that three oral presentations detailing the final results from the...
June 01, 2014 19:15 ET | Source: TESARO, Inc.

Tesaro Summarizes Phase 3 Rolapitant Data Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting and Provides an Update on Niraparib Development Strategy

Oral Rolapitant New Drug Application (NDA) Submission on Track for Mid-2014 Development Plans for Niraparib in Small Cell Lung Cancer and First-Line Ovarian Cancer Announced CHICAGO, June...